CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7 More Clinical Sites

Sites in Europe and Asia add to patient enrollment and position Company to apply for global regulatory approvals December 8, 2014 CEL-SCI Corporation today announced that during November it has added seven new clinical sites to its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). Patient screening has begun at new clinical …

CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial

September 3, 2014 CEL-SCI Corporation today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients. “Given that summer months generally have a slower …

CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada

CHUQ is the latest medical center to join CEL-SCI’s trial in North America August 19th, 2014 CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has added Centre Hospitalier Universitaire de Québec (CHUQ)’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America. …

CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial

August 1st, 2014 –14 patients enrolled in July brings total enrollment to over one-quarter of the 880 patients planned for enrollment by the end of 2015 CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and …

CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka

15th nation to join world’s largest Head and Neck cancer Phase III trial July 17, 2014 CEL-SCI Corporation today announced that Sri Lanka’s Ministry of Health has cleared the Company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Sri Lanka. This follows similar clearance to conduct the …

CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment

Pre-clinical studies show CEL-SCI’s LEAPS technology prevented the development and lessened the severity of rheumatoid arthritis July 15, 2014 CEL-SCI Corporation announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS), which is part of the National Institutes of …

CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI’S Phase III Head and Neck Cancer Trial into Austria

July 8, 2014 CEL-SCI Corporation today announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the Company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Austria is the 14th country to participate in CEL-SCI’s trial which is already active in numerous …